Sickle cell disease and coronavirus disease-2019 (COVID-19) infection : a single-center experience
© The Author(s) 2023. Published by Oxford University Press on behalf of Postgraduate Medical Journal. All rights reserved. For Permissions, please email: journals.permissionsoup.com..
PURPOSE: Sickle cell disease (SCD) has been found to be associated with an increased risk of hospitalization and death from coronavirus disease-2019 (COVID-19). We sought to study clinical outcomes in patients with SCD and a diagnosis of COVID-19 infection.
METHODS: We conducted a retrospective analysis of adult patients (>18 years) with SCD who were diagnosed with COVID-19 infection between 1 March 2020 and 31 March 2021. Data on baseline characteristics and overall outcomes were collected and analyzed using SAS 9.4 for Windows.
RESULTS: A total of 51 patients with SCD were diagnosed with COVID-19 infection in the study period, out of which 39.3% were diagnosed and managed in the outpatient setting/emergency room (ER) and 60.3% in the inpatient setting. Disease-modifying therapy such as hydroxyurea did not impact inpatient vs outpatient/ER management (P > 0.05). Only 5.71% (n = 2) required intensive care unit admission and were mechanically ventilated and 3.9% (2 patients) died of complications of COVID-19 infection.
CONCLUSION: We identified a lower mortality (3.9%) rate among patients in our cohort in comparison to previous studies and a higher burden of inpatient hospitalizations as compared to outpatient/ER management. Further prospective data are needed to validate these findings. Key messages What is already known on this topic COVID-19 has been shown to have a disproportionately unfavorable impact on African Americans, including longer hospital stays, higher rates of ventilator dependence, and a higher overall mortality rate. Limited data also suggest that sickle cell disease (SCD) is associated with an increased risk of hospitalization and death from COVID-19. What this study adds Our analysis did not show a higher mortality due to COVID-19 in patients with SCD. However, we identified a high burden of inpatient hospitalizations in this population. COVID-19-related outcomes did not improve with the use of disease-modifying therapies. How this study might affect research, practice, or policy These results will aid in decision making for triage of patients with COVID-19 and SCD and ensure the most appropriate use of healthcare resources. Our analysis underscores the need for more robust data to identify patients at higher risk of severe disease and/or mortality, necessitating inpatient hospitalization and aggressive management.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:99 |
|---|---|
| Enthalten in: |
Postgraduate medical journal - 99(2023), 1175 vom: 22. Aug., Seite 1008-1012 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Devarashetty, Sindhu P [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
African Americans |
|---|
| Anmerkungen: |
Date Completed 23.08.2023 Date Revised 23.08.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/postmj/qgad033 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359002617 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359002617 | ||
| 003 | DE-627 | ||
| 005 | 20231226075933.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/postmj/qgad033 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1196.xml |
| 035 | |a (DE-627)NLM359002617 | ||
| 035 | |a (NLM)37399057 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Devarashetty, Sindhu P |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sickle cell disease and coronavirus disease-2019 (COVID-19) infection |b a single-center experience |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.08.2023 | ||
| 500 | |a Date Revised 23.08.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of Postgraduate Medical Journal. All rights reserved. For Permissions, please email: journals.permissionsoup.com. | ||
| 520 | |a PURPOSE: Sickle cell disease (SCD) has been found to be associated with an increased risk of hospitalization and death from coronavirus disease-2019 (COVID-19). We sought to study clinical outcomes in patients with SCD and a diagnosis of COVID-19 infection | ||
| 520 | |a METHODS: We conducted a retrospective analysis of adult patients (>18 years) with SCD who were diagnosed with COVID-19 infection between 1 March 2020 and 31 March 2021. Data on baseline characteristics and overall outcomes were collected and analyzed using SAS 9.4 for Windows | ||
| 520 | |a RESULTS: A total of 51 patients with SCD were diagnosed with COVID-19 infection in the study period, out of which 39.3% were diagnosed and managed in the outpatient setting/emergency room (ER) and 60.3% in the inpatient setting. Disease-modifying therapy such as hydroxyurea did not impact inpatient vs outpatient/ER management (P > 0.05). Only 5.71% (n = 2) required intensive care unit admission and were mechanically ventilated and 3.9% (2 patients) died of complications of COVID-19 infection | ||
| 520 | |a CONCLUSION: We identified a lower mortality (3.9%) rate among patients in our cohort in comparison to previous studies and a higher burden of inpatient hospitalizations as compared to outpatient/ER management. Further prospective data are needed to validate these findings. Key messages What is already known on this topic COVID-19 has been shown to have a disproportionately unfavorable impact on African Americans, including longer hospital stays, higher rates of ventilator dependence, and a higher overall mortality rate. Limited data also suggest that sickle cell disease (SCD) is associated with an increased risk of hospitalization and death from COVID-19. What this study adds Our analysis did not show a higher mortality due to COVID-19 in patients with SCD. However, we identified a high burden of inpatient hospitalizations in this population. COVID-19-related outcomes did not improve with the use of disease-modifying therapies. How this study might affect research, practice, or policy These results will aid in decision making for triage of patients with COVID-19 and SCD and ensure the most appropriate use of healthcare resources. Our analysis underscores the need for more robust data to identify patients at higher risk of severe disease and/or mortality, necessitating inpatient hospitalization and aggressive management | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a African Americans | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a outcomes | |
| 650 | 4 | |a sickle cell disease | |
| 700 | 1 | |a Grewal, Udhayvir S |e verfasserin |4 aut | |
| 700 | 1 | |a Le Blanc, Kimberly |e verfasserin |4 aut | |
| 700 | 1 | |a Walton, Jacqueline |e verfasserin |4 aut | |
| 700 | 1 | |a Jones, Tabitha |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Runhua |e verfasserin |4 aut | |
| 700 | 1 | |a Master, Samip R |e verfasserin |4 aut | |
| 700 | 1 | |a Mansour, Richard P |e verfasserin |4 aut | |
| 700 | 1 | |a Ramadas, Poornima |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Postgraduate medical journal |d 1925 |g 99(2023), 1175 vom: 22. Aug., Seite 1008-1012 |w (DE-627)NLM000043753 |x 1469-0756 |7 nnns |
| 773 | 1 | 8 | |g volume:99 |g year:2023 |g number:1175 |g day:22 |g month:08 |g pages:1008-1012 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/postmj/qgad033 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 99 |j 2023 |e 1175 |b 22 |c 08 |h 1008-1012 | ||